Its screen for selected variants of some disease-linked genes gives customers an incomplete picture of their risk—do they know?

Companies are building platforms based on blockchain technology to let individuals control and directly profit from their genomic and medical information.

Data don’t support many direct-to-consumer products, from telomere assessments to bespoke diets based on genetic sequences.

A security researcher found the email addresses and encrypted passwords of more than 92 million users of the genealogy site on a private server outside the company.

Luna DNA, Nebula Genomics, and other “bio-brokers” will allow customers to make money by granting access to their genetic and personal information for research purposes.

Rather, the breast cancer mutation screen was classified as a type of medical device with obligations for the company to reduce risks to customers.

The agency gave personal genomics company 23andMe the green light to screen samples for breast cancer–related genetic mutations.

An exploration of the genetics of earlobe attachment is just the latest collaborative research project to come out of the personal genetic testing company.

23andMe customers can now receive information about genetic risk for diseases including Parkinson’s and celiac.